Bob Oranje1, Birte Y Glenthøj2. 1. Center for Neuropsychiatric Schizophrenia Research (CNSR) and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Copenhagen University Hospital, Psychiatric Center Glostrup, Glostrup, Denmark;Faculty of Health Sciences, Department of Neurology, Psychiatry, and Sensory Sciences, University of Copenhagen, Copenhagen, Denmark B.Oranje@cnsr.dk. 2. Center for Neuropsychiatric Schizophrenia Research (CNSR) and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Copenhagen University Hospital, Psychiatric Center Glostrup, Glostrup, Denmark;Faculty of Health Sciences, Department of Neurology, Psychiatry, and Sensory Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: Sensory gating deficits are among the core features of schizophrenia. Recently, we reported significantly increased sensorimotor gating following additional administration of single dosages of clonidine to the treatment of stably medicated patients with schizophrenia who, in spite of their medication, showed gating deficits. In the current study, we investigated whether this result is generalizable to filtering of sensory information as a whole, by examining clonidine's effect on P50 suppression in the same group of patients. METHODS: In a double-blind, placebo-controlled, randomized yet balanced cross-over design, 20 male schizophrenia patients on stable medication were assessed in a psychophysiological test battery, including a sensory gating paradigm on 5 occasions: once after oral administration of placebo and after single doses of 25, 50, 75, and 150 µg of clonidine. Their results were compared with 20 age-matched healthy male volunteers, who received no treatment. RESULTS: Patients showed significantly reduced levels of P50 suppression in the placebo session compared with controls. All dosages of clonidine significantly diminished these deficits to such levels that they no longer differed significantly from the healthy controls (except the highest dose). CONCLUSIONS: This is the first study to show that even a single low dose of clonidine administered to stably medicated patients with schizophrenia not only significantly increases their levels of P50 suppression but also normalizes them. The results indicate that α2-noradrenergic agonists are capable of normalizing levels of P50 gating, which has a potentially high clinical relevance for the medical treatment of schizophrenia.
RCT Entities:
BACKGROUND: Sensory gating deficits are among the core features of schizophrenia. Recently, we reported significantly increased sensorimotor gating following additional administration of single dosages of clonidine to the treatment of stably medicated patients with schizophrenia who, in spite of their medication, showed gating deficits. In the current study, we investigated whether this result is generalizable to filtering of sensory information as a whole, by examining clonidine's effect on P50 suppression in the same group of patients. METHODS: In a double-blind, placebo-controlled, randomized yet balanced cross-over design, 20 male schizophreniapatients on stable medication were assessed in a psychophysiological test battery, including a sensory gating paradigm on 5 occasions: once after oral administration of placebo and after single doses of 25, 50, 75, and 150 µg of clonidine. Their results were compared with 20 age-matched healthy male volunteers, who received no treatment. RESULTS:Patients showed significantly reduced levels of P50 suppression in the placebo session compared with controls. All dosages of clonidine significantly diminished these deficits to such levels that they no longer differed significantly from the healthy controls (except the highest dose). CONCLUSIONS: This is the first study to show that even a single low dose of clonidine administered to stably medicated patients with schizophrenia not only significantly increases their levels of P50 suppression but also normalizes them. The results indicate that α2-noradrenergic agonists are capable of normalizing levels of P50 gating, which has a potentially high clinical relevance for the medical treatment of schizophrenia.
Authors: Bodil Aggernaes; Birte Y Glenthoj; Bjorn H Ebdrup; Hans Rasmussen; Henrik Lublin; Bob Oranje Journal: Int J Neuropsychopharmacol Date: 2010-07-16 Impact factor: 5.176
Authors: Roger S McIntyre; David J Muzina; Amanda Adams; Maria Teresa C Lourenco; Candy W Y Law; Joanna K Soczynska; Hanna O Woldeyohannes; Jay Nathanson; Sidney H Kennedy Journal: Expert Opin Pharmacother Date: 2009-12 Impact factor: 3.889
Authors: Philipp A Csomor; Renée R Stadler; Joram Feldon; Benjamin K Yee; Mark A Geyer; Franz X Vollenweider Journal: Neuropsychopharmacology Date: 2007-04-25 Impact factor: 7.853
Authors: Terry E Goldberg; Robert S Goldman; Katherine E Burdick; Anil K Malhotra; Todd Lencz; Raman C Patel; Margaret G Woerner; Nina R Schooler; John M Kane; Delbert G Robinson Journal: Arch Gen Psychiatry Date: 2007-10
Authors: Veena Kumari; Dominic Fannon; Mark A Geyer; Preethi Premkumar; Elena Antonova; Andrew Simmons; Elizabeth Kuipers Journal: Cortex Date: 2008-01-20 Impact factor: 4.027
Authors: Boris B Quednow; Anne Schmechtig; Ulrich Ettinger; Nadine Petrovsky; David A Collier; Franz X Vollenweider; Michael Wagner; Veena Kumari Journal: Biol Psychiatry Date: 2009-06-28 Impact factor: 13.382
Authors: Louise Witten; Jesper Frank Bastlund; Birte Y Glenthøj; Christoffer Bundgaard; Björn Steiniger-Brach; Arne Mørk; Bob Oranje Journal: Neuropsychopharmacology Date: 2015-07-01 Impact factor: 7.853